#China #Shanghai #NASDAQ #Alamar Biosciences #Qiming Venture Partners

Alamar Biosciences' Historic NASDAQ Listing

In a significant milestone for the biotechnology sector, Alamar Biosciences, recognized as a trailblazer in precision proteomics, made its debut on the NASDAQ Stock Exchange on April 17, 2026, Beijing Time. The company, backed by Qiming Venture Partners, launched its shares at an initial price of $17, which quickly surged to $22.6 upon opening, with a market capitalization reaching around $1.5 billion.

Alamar Biosciences has been at the forefront of innovating proteomics technologies since its inception in 2018. Under the leadership of Qiming Venture Partners, which has been a steadfast supporter since Alamar's early funding rounds, the company has successfully developed groundbreaking tools designed to enhance protein analysis. Leading this segment is their proprietary NULISA™ technology, which addresses some of the critical gaps left by traditional proteomics methods, allowing for ultra-sensitive and specific protein detection. This technology has given researchers and medical professionals access to protein biomarkers at extraordinarily low concentrations, paving the way for early disease detection and precision diagnostics.

Moreover, as part of its commitment to advancing the field, Alamar has introduced the ARGO™ HT fully automated high-throughput system. This innovative platform streamlines the workflow from sample collection to result analysis, enabling a more efficient approach to protein detection and enhancing product market penetration. As of late 2025, over 100 ARGO™ HT systems had been installed globally, catering to more than 300 customers in 25 different countries. This rapid growth exemplifies Alamar's success in expanding its reach and influence, further solidified by the publication of over 100 scientific articles leveraging its technology and products.

William Hu, Managing Partner at Qiming Venture Partners, expressed his congratulations to Alamar on the successful public listing, emphasizing the potential of ultra-high sensitivity proteomics in transforming early disease screening and precision diagnostics. He reaffirmed Qiming's belief in Alamar's capacity to drive significant advancements in healthcare technologies and improve accessibility to essential diagnostic solutions. “We are proud to have supported Alamar through its growth journey, and we are excited to see how it continues to lead in the proteomics space,” Hu stated.

As Alamar transition into its public phase, it stands as a testament to how innovative biotechnology firms can impact global health outcomes. Its continuing efforts to refine and improve protein analysis technologies promise a brighter future for the field of diagnostics and personalized medicine. By addressing current limitations, Alamar is well-positioned to enhance diagnostic capabilities, thereby generating long-term value for patients and healthcare systems worldwide.

Qiming Venture Partners, since its founding in 2006, has managed substantial capital across multiple funds and has successfully backed numerous companies in both technology and healthcare industries, witnessing over 210 portfolio companies achieve IPO exits on various global exchanges. This track record cements its role not just as a financial backer but as a significant contributor to the growth of innovative companies that shape the future of multiple sectors.

As Alamar Biosciences embarks on this new chapter, stakeholders and industry observers eagerly anticipate the advancements and contributions it will bring to the biotechnology landscape, with the potential to redefine standards for precision diagnostics and proteomics.